Select country change
Shopping cart (0 , 0,00 ) Menu Search
Distributed product


  • Regulatory status:RUO
  • Type:Competitive ELISA, Immobilized antigen
  • Other names:Asymmetric Dimethylarginine
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

REA201/96 96 wells (1 kit)
PubMed Product Details
Technical Data


Competitive ELISA, Immobilized antigen


Serum, Plasma-EDTA

Sample Requirements

20 μl/well


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.1–5.0 µmol/l

Limit of Detection

0.05 μmol/l

Intra-assay (Within-Run)

CV = 6.1%

Inter-assay (Run-to-Run)

CV = 9.5%

Spiking Recovery


Dilutation Linearity




  • European Union: for in vitro diagnostic use
  • Rest of the world: for research use only!
  • Disposable gloves should be used.
  • Material of animal origin used in the preparation of the kit has been obtained from animals certified as healthy but these materiále should be handled as potentially infectious.

Research topic

Blood pressure regulation and NO metabolism, Cardiovascular disease


The vascular endothelium plays a central role in the regulation of vascular structure and function, mainly due to the formation of endothelium-derived nitric oxide (NO). NO is formed by the enzyme NO synthetase (NOS) from the amino acid precursor L-arginine. NOS activity can be downregulated by ADMA, an endogenous inhibitor of NOS. Elevated ADMA levels in plasma have been found in clinical studies including patients with hypercholeste­rolemia, hypertension, chronic heart failure, chronic renal failure and other internal disorders. ADMA may have diagnostic relevance as a novel cardiovascular risk marker.

References to Product


  • Alan C,Kurt HA, Topaloğlu N, Ersay AR, Çakir DU, Baştürk G. Nitric oxide and asymmetric dimethyl arginine (ADMA) levels in an experimental hydronephrotic kidney caused by unilateral partial ureteral obstruction. Int Braz J Urol. May-June 2016;Vol. 42 (3)
  • Antoniades C, Tousoulis D, Marinou K, Vasiliadou C, Tentolouris C, Bouras G, Pitsavos C, Stefanadis C. Asymmetrical dimethylarginine regulates endothelial function in methionine-induced but not in chronic homocystinemia in humans: effect of oxidative stress and proinflammatory cytokines. Am J Clin Nutr. 2006 Oct;84 (4):781-8
  • Boger RH. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med. 2006;38 (2):126-36
  • Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Pinsky DJ, Marmur JD. Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography. Coron Artery Dis. 2009 Mar;20 (2):112-7
  • Charitidou C, Farmakiotis D, Zournatzi V, Pidonia I, Pegiou T, Karamanis N, Hatzistilianou M, Katsikis I, Panidis D. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome. Atherosclerosis. 2008 Feb;196 (2):958-65
  • El-Mesallamy HO, Abdel Hamid SG, Gad MZ. Oxidative stress and asymmetric dimethylarginine are associated with cardiovascular complications in hemodialysis patients: improvements by L-arginine intake. Kidney Blood Press Res. 2008;31 (3):189-95
  • Ferroni P, Guagnano MT, Falco A, Paoletti V, Manigrasso MR, Michetti N, Santilli F, Guadagni F, Basili S, Davi G. Association of low-grade inflammation and platelet activation in patients with hypertension with microalbuminuria. Clin Sci (Lond). 2008 Mar;114 (6):449-55
  • Galle J, Schwedhelm E, Pinnetti S, Boger RH, Wanner C. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant. 2008 Oct;23 (10):3174-83
  • Guagnano MT, Ferroni P, Santilli F, Paoletti V, Manigrasso MR, Pescara L, Cuccurullo C, Ciabattoni G, Davi G. Determinants of platelet activation in hypertensives with microalbuminuria. Free Radic Biol Med. 2009 Apr 1;46 (7):922-7
  • Gulhan I, Kebapcilar L, Alacacioglu A, Bilgili S, Kume T, Aytac B, Gunaydin R. Postmenopausal women with osteoporosis may be associated with high endothelin-1. Gynecol Endocrinol. 2009 Oct;25 (10):674-8
  • Horowitz JD, Heresztyn T. An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: methodological considerations. J Chromatogr B Analyt Technol . 2007 May 15;851 (1-2):42-50
  • Iribarren C, Husson G, Sydow K, Wang BY, Sidney S, Cooke JP. Asymmetric dimethyl-arginine and coronary artery calcification in young adults entering middle age: the CARDIA Study. Eur J Cardiovasc Prev Rehabil. 2007 Apr;14 (2):222-9
  • Jacobi J, Maas R, Cordasic N, Koch K, Schmieder RE, Boger RH, Hilgers KF. Role of asymmetric dimethylarginine for angiotensin II-induced target organ damage in mice. Am J Physiol Heart Circ Physio. 2008 Feb;294 (2):H1058-66
  • Konishi H, Sydow K, Cooke JP. Dimethylarginine dimethylaminohydrolase promotes endothelial repair after vascular injury. J Am Coll Cardiol. 2007 Mar 13;49 (10):1099-105
  • Konukoglu D, Uzun H, Firtina S, Cigdem Arica P, Kocael A, Taskin M. Plasma adhesion and inflammation markers: asymmetrical dimethyl-L-arginine and secretory phospholipase A2 concentrations before and after laparoscopic gastric banding in morbidly obese patients. Obes Surg. 2007 May;17 (5):672-8
  • Korish AA, Arafah MM. Catechin combined with vitamins C and E ameliorates insulin resistance (IR) and atherosclerotic changes in aged rats with chronic renal failure (CRF). Arch Gerontol Geriatr. 2008 Jan-Feb;46 (1):25-39
  • Krempl TK, Maas R, Sydow K, Meinertz T, Boger RH, Kahler J. Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J. 2005 Sep;26 (18):1846-51
  • Melikian N, Wheatcroft SB, Ogah OS, Murphy C, Chowienczyk PJ, Wierzbicki AS, Sanders TA, Jiang B, Duncan ER, Shah AM, Kearney MT. Asymmetric dimethylarginine and reduced nitric oxide bioavailability in young Black African men. Hypertension. 2007 Apr;49 (4):873-7
  • Nagasaka H, Okano Y, Tsukahara H, Shigematsu Y, Momoi T, Yorifuji J, Miida T, Ohura T, Kobayashi K, Saheki T, Hirano K, Takayanagi M, Yorifuji T. Sustaining hypercitrullinemia, hypercholesterolemia and augmented oxidative stress in Japanese children with aspartate/glutamate carrier isoform 2-citrin-deficiency even during the silent period. Mol Genet Metab. 2009 May;97 (1):21-6
  • Nagasaka H, Tsukahara H, Yorifuji T, Miida T, Murayama K, Tsuruoka T, Takatani T, Kanazawa M, Kobayashi K, Okano Y, Takayanagi M. Evaluation of endogenous nitric oxide synthesis in congenital urea cycle enzyme defects. Metabolism. 2009 Mar;58 (3):278-82
  • O'Dwyer MJ, Dempsey F, Crowley V, Kelleher DP, McManus R, Ryan T. Septic shock is correlated with asymmetrical dimethyl arginine levels, which may be influenced by a polymorphism in the dimethylarginine dimethylaminohydrolase II gene: a prospective observational study. Crit Care. 2006;10 (5):R139
  • Oguz A, Uzunlulu M, Yorulmaz E, Yalcin Y, Hekim N, Fici F. Effect of nebivolol and metoprolol treatments on serum asymmetric dimethylarginine levels in hypertensive patients with type 2 diabetes mellitus. Anadolu Kardiyol Derg. 2007 Dec;7 (4):383-7
  • Onat A, Hergenc G, Can G, Karabulut A. Serum asymmetric dimethylarginine levels among Turks: association with metabolic syndrome in women and tendency to decrease in smokers. Turk Kardiyol Dern Ars. 2008 Jan;36 (1):7-13
  • Panichi V, Mantuano E, Paoletti S, Santi S, Manca Rizza G, Cutrupi S, Pizzini P, Spoto B, Tripepi G, Zoccali C. Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. J Nephrol. 2008 Jan-Feb;21 (1):38-44
  • Potena L, Fearon WF, Sydow K, Holweg C, Luikart H, Chin C, Weisshaar D, Mocarski ES, Lewis DB, Valantine HA, Cooke JP. Asymmetric dimethylarginine and cardiac allograft vasculopathy progression: modulation by sirolimus. Transplantation. 2008 Mar 27;85 (6):827-33
  • Reimann M, Ziemssen T, Huisman HW, Schutte R, Malan L, Van Rooyen JM, Boger RH, Malan NT, Schutte AE. Ethnic-specific correlations of visfatin with circulating markers of endothelial inflammation and function. Obesity (Silver Spring). 2009 Dec;17 (12):2210-5
  • Santilli F, Romano M, Recchiuti A, Dragani A, Falco A, Lessiani G, Fioritoni F, Lattanzio S, Mattoscio D, De Cristofaro R, Rocca B, Davi G. Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients. Blood. 2008 Aug 15;112 (4):1085-90
  • Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, Jachmann N, Post F, Peetz D, Bickel C, Cambien F, Tiret L, Munzel T. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res. 2005 Sep 2;97 (5):e53-9
  • Schulze F, Carter AM, Schwedhelm E, Ajjan R, Maas R, von Holten RA, Atzler D, Grant PJ, Boger RH. Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Atherosclerosis. 2010 Feb;208 (2):518-23
  • Schulze F, Maas R, Freese R, Schwedhelm E, Silberhorn E, Boger RH. Determination of a reference value for N(G), N(G)-dimethyl-L-arginine in 500 subjects. Eur J Clin Invest. 2005 Oct;35 (10):622-6
  • Schulze F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J, Cooke JP, Boger RH. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med. 2004;42 (12):1377-83
  • Sibal L, Agarwal SC, Schwedhelm E, Luneburg N, Boger RH, Home PD. A study of endothelial function and circulating asymmetric dimethylarginine levels in people with Type 1 diabetes without macrovascular disease or microalbuminuria. Cardiovasc Diabetol. 2009;8:27
  • Siroka R, Trefil L, Rajdl D, Racek J, Cibulka R. Asymmetric dimethylarginine--comparison of HPLC and ELISA methods. J Chromatogr B Analyt Technol . 2007 May 1;850 (1-2):586-7
  • Sydow K, Fortmann SP, Fair JM, Varady A, Hlatky MA, Go AS, Iribarren C, Tsao PS. Distribution of asymmetric dimethylarginine among 980 healthy, older adults of different ethnicities. Clin Chem. 2010 Jan;56 (1):111-20
  • Tsukahara H, Ohta N, Tokuriki S, Nishijima K, Kotsuji F, Kawakami H, Ohta N, Sekine K, Nagasaka H, Mayumi M. Determination of asymmetric dimethylarginine, an endogenous nitric oxide synthase inhibitor, in umbilical blood. Metabolism. 2008 Feb;57 (2):215-20
  • Uzun H, Konukoglu D, Besler M, Erdenen F, Sezgin C, Muderrisoglu C. The effects of renal replacement therapy on plasma, asymmetric dimethylarginine, nitric oxide and C-reactive protein levels. Clin Invest Med. 2008;31 (1):E1-7
  • Vladimirova-Kitova L, Deneva T, Angelova E, Nikolov F, Marinov B, Mateva N. Relationship of asymmetric dimethylarginine with flow-mediated dilatation in subjects with newly detected severe hypercholesterolemia. Clin Physiol Funct Imaging. 2008 Nov;28 (6):417-25
  • Vladimirova-Kitova L, Deneva T, Marinov B. Predictors of the intima-media thickness of carotid artery in asymptomatic newly detected severe hypercholesterolemic patients. Clin Physiol Funct Imaging. 2010 Jul;30 (4):250-9
  • Vladimirova-Kitova L, Terzieva D, Marinov B. Intima-media thickness and flow-mediated vasodilation in asymptomatic subjects with newly detected severe hypercholesterolemia. Echocardiography. 2009 Oct;26 (9):1060-8
  • Wanby P, Nilsson I, Brudin L, Nyhammar I, Gustafsson I, Carlsson M. Increased plasma levels of asymmetric dimethylarginine in patients with carotid stenosis: no evidence for the role of the common FABP2 A54T gene polymorphism. Acta Neurol Scand. 2007 Feb;115 (2):90-6
  • Wang TD, Chen WJ, Cheng WC, Lin JW, Chen MF, Lee YT. Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. Am J Cardiol. 2006 Oct 15;98 (8):1057-62
  • Wipff J, Avouac J, Borderie D, Zerkak D, Lemarechal H, Kahan A, Boileau C, Allanore Y. Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. Rheumatology (Oxford). 2008 Jul;47 (7):972-5
References to Summary

References to ADMA

  • Boger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res. 2003 Oct 1;59 (4):824-33
  • Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J. 2003 Nov;24 (21):1912-9
  • Nijveldt RJ, Teerlink T, Van Der Hoven B, Siroen MP, Kuik DJ, Rauwerda JA, van Leeuwen PA. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr. 2003 Feb;22 (1):23-30
  • Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nicolaides KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet. 2003 May 3;361 (9368):1511-7
  • Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 2002 Mar 20;287 (11):1420-6
  • Testa A, Spoto B, Tripepi G, Mallamaci F, Malatino L, Fatuzzo P, Maas R, Boeger R, Zoccali C. The GLU298ASP variant of nitric oxide synthase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease. J Hypertens. 2005 Oct;23 (10):1825-30
  • Testa A, Spoto B, Tripepi G, Mallamaci F, Malatino L, Fatuzzo P, Maas R, Boeger R, Zoccali C. The GLU298ASP variant of nitric oxide synthase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease. J Hypertens. 2005 Oct;23 (10):1825-30
  • Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992 Mar 7;339 (8793):572-5
  • Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001 Dec 22-29;358 (9299):2113-7
Related Products Documents